top of page

Generate Biomedicines' Mike Nally on Thursday's $273M Series C and computational drug development

Mike Nally describes near term programs Generate is working on and how he sees computational advances changing where the field is headed over the longer term.



Comentarios


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page